請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/79033
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 郭錦樺(Ching-Hua Kuo) | |
dc.contributor.author | Ren-Shiang Jhang | en |
dc.contributor.author | 張人祥 | zh_TW |
dc.date.accessioned | 2021-07-11T15:38:18Z | - |
dc.date.available | 2021-10-11 | |
dc.date.copyright | 2018-10-11 | |
dc.date.issued | 2018 | |
dc.date.submitted | 2018-08-14 | |
dc.identifier.citation | 1. Cosmi, B., An update on the pharmaceutical management of thrombosis. Expert Opinion on Pharmacotherapy, 2016. 17(16): p. 2149-2164.
2. Santarpia, G., et al., Clinical Significance of Non-Vitamin K Antagonist Oral Anticoagulants in the Management of Atrial Fibrillation. Circulation Journal, 2015. 79(5): p. 914-923. 3. Kalabalik, J., et al., Use of Non-Vitamin K Antagonist Oral Anticoagulants in Special Patient Populations with Nonvalvular Atrial Fibrillation: A Review of the Literature and Application to Clinical Practice. Drugs, 2015. 75(9): p. 979-998. 4. Heidbuchel, H., et al., Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary. European Heart Journal, 2017. 38(27): p. 2137-2149. 5. Zulkifly, H., G.Y.H. Lip, and D.A. Lane, Epidemiology of atrial fibrillation. Int J Clin Pract, 2018. 6. Lane Da, S.F., Lip Gyh, et.al. , Temporal Trends in Incidence, Prevalence, and Mortality of Atrial Fibrillation in Primary Care. Physicians' Academy for Cardiovascular Education. 7. Morais, J. and R. De Caterina, Stroke Prevention in Atrial Fibrillation: A Clinical Perspective on Trials of the Novel Oral Anticoagulants. Cardiovascular Drugs and Therapy, 2016. 30(2): p. 201-214. 8. Tripodi, A., The Laboratory and the New Oral Anticoagulants. Clinical Chemistry, 2013. 59(2): p. 353-362. 9. Cihak, R., L. Haman, and M. Taborsky, 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS Summary of the document prepared by the Czech Society of Cardiology. Cor Et Vasa, 2016. 58(6): p. E636-E683. 10. Lippi, G. and E.J. Favaloro, Recent guidelines and recommendations for laboratory assessment of the direct oral anticoagulants (DOACs): is there consensus? Clinical Chemistry and Laboratory Medicine, 2015. 53(2): p. 185-197. 11. Cuker, A., Laboratory measurement of the non-vitamin K antagonist oral anticoagulants: selecting the optimal assay based on drug, assay availability, and clinical indication. Journal of Thrombosis and Thrombolysis, 2016. 41(2): p. 241-247. 12. Di Minno, A., et al., Old and new oral anticoagulants: Food, herbal medicines and drug interactions. Blood Reviews, 2017. 31(4): p. 193-203. 13. Forbes, H.L. and T.M. Polasek, Potential drug-drug interactions with direct oral anticoagulants in elderly hospitalized patients. Therapeutic Advances in Drug Safety, 2017. 8(10): p. 319-328. 14. Douxfils, J., et al., Non-VKA Oral Anticoagulants: Accurate Measurement of Plasma Drug Concentrations. Biomed Research International, 2015: p. 13. 15. Douxfils, J. and R.C. Gosselin, Laboratory Assessment of Direct Oral Anticoagulants. Seminars in Thrombosis and Hemostasis, 2017. 43(3): p. 277-290. 16. Douxfils, J., et al., Mass spectrometry in the therapeutic drug monitoring of direct oral anticoagulants. Useful or useless? Trac-Trends in Analytical Chemistry, 2016. 84: p. 41-50. 17. Wiesen, M.H.J., et al., Paramagnetic micro-particles as a tool for rapid quantification of apixaban, dabigatran, edoxaban and rivaroxaban in human plasma by UHPLC-MS/MS. Clin Chem Lab Med, 2017. 55(9): p. 1349-1359. 18. Schmitz, E.M.H., et al., Determination of dabigatran, rivaroxaban and apixaban by ultra-performance liquid chromatography - tandem mass spectrometry (UPLC-MS/MS) and coagulation assays for therapy monitoring of novel direct oral anticoagulants. Journal of Thrombosis and Haemostasis, 2014. 12(10): p. 1636-1646. 19. Gous, T., et al., Measurement of the Direct Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in Human Plasma Using Turbulent Flow Liquid Chromatography With High-Resolution Mass Spectrometry. Therapeutic Drug Monitoring, 2014. 36(5): p. 597-605. 20. Li, W.K. and F.L.S. Tse, Dried blood spot sampling in combination with LC-MS/MS for quantitative analysis of small molecules. Biomedical Chromatography, 2010. 24(1): p. 49-65. 21. Mei, J.V., et al., Use of filter paper for the collection and analysis of human whole blood specimens. Journal of Nutrition, 2001. 131(5): p. 1631S-1636S. 22. Wagner, M., et al., The use of mass spectrometry to analyze dried blood spots. Mass Spectrometry Reviews, 2016. 35(3): p. 361-438. 23. Enderle, Y., K. Foerster, and J. Burhenne, Clinical feasibility of dried blood spots: Analytics, validation, and applications. Journal of Pharmaceutical and Biomedical Analysis, 2016. 130: p. 231-243. 24. Wang, Q., et al., Mass spectral study of storage conditions and paper substrates on the degradation and analytical sensitivity of therapeutic drugs in dried blood spots. International Journal of Mass Spectrometry, 2015. 387: p. 38-44. 25. Nijenhuis, C.M., et al., The Use of Dried Blood Spots for Pharmacokinetic Monitoring of Vemurafenib Treatment in Melanoma Patients. Journal of Clinical Pharmacology, 2016. 56(10): p. 1307-1312. 26. Wilhelm, A.J., J.C.G. den Burger, and E.L. Swart, Therapeutic Drug Monitoring by Dried Blood Spot: Progress to Date and Future Directions. Clinical Pharmacokinetics, 2014. 53(11): p. 961-973. 27. McDade, T.W., Development and Validation of Assay Protocols for use with Dried Blood Spot Samples. American Journal of Human Biology, 2014. 26(1): p. 1-9. 28. ter Heine, R., et al., Clinical evaluation of the determination of plasma concentrations of darunavir, etravirine, raltegravir and ritonavir in dried blood spot samples. Bioanalysis, 2011. 3(10): p. 1093-1097. 29. Martial, L.C., et al., Cost Evaluation of Dried Blood Spot Home Sampling as Compared to Conventional Sampling for Therapeutic Drug Monitoring in Children. PLoS One, 2016. 11(12): p. 17. 30. Edelbroek, P.M., J. van der Heijden, and L.M. Stolk, Dried blood spot methods in therapeutic drug monitoring: methods, assays, and pitfalls. Ther Drug Monit, 2009. 31(3): p. 327-36. 31. Wagner, M., et al., The use of mass spectrometry to analyze dried blood spots. Mass Spectrom Rev, 2016. 35(3): p. 361-438. 32. Abu-Rabie, P., et al., Investigation of Different Approaches to Incorporating Internal Standard in DBS Quantitative Bioanalytical Workflows and Their Effect on Nullifying Hematocrit-Based Assay Bias. Analytical Chemistry, 2015. 87(9): p. 4996-5003. 33. Mee, J.M.L., J. Korth, and B. Halpern, RAPID AND QUANTITATIVE BLOOD ANALYSIS FOR FREE FATTY-ACIDS BY CHEMICAL IONIZATION MASS-SPECTROMETRY. Analytical Letters, 1976. 9(12): p. 1075-1083. 34. Spooner, N., R. Lad, and M. Barfield, Dried Blood Spots as a Sample Collection Technique for the Determination of Pharmacokinetics in Clinical Studies: Considerations for the Validation of a Quantitative Bioanalytical Method. Analytical Chemistry, 2009. 81(4): p. 1557-1563. 35. Edelbroek, P.M., J. van der Heijden, and L.M.L. Stolk, Dried Blood Spot Methods in Therapeutic Drug Monitoring: Methods, Assays, and Pitfalls. Therapeutic Drug Monitoring, 2009. 31(3): p. 327-336. 36. Koal, T., et al., Quantification of antiretroviral drugs in dried blood spot samples by means of liquid chromatography/tandem mass spectrometry. Rapid Communications in Mass Spectrometry, 2005. 19(21): p. 2995-3001. 37. Martin, N.J. and H.J. Cooper, Challenges and opportunities in mass spectrometric analysis of proteins from dried blood spots. Expert Review of Proteomics, 2014. 11(6): p. 685-695. 38. Liao, H.W., et al., Estimation and Correction of the Blood Volume Variations of Dried Blood Spots Using a Postcolumn Infused-Internal Standard Strategy with LC-Electrospray Ionization-MS. Analytical Chemistry, 2016. 88(12): p. 6457-6464. 39. Denniff, P. and N. Spooner, The effect of hematocrit on assay bias when using DBS samples for the quantitative bioanalysis of drugs. Bioanalysis, 2010. 2(8): p. 1385-1395. 40. De Kesel, P.M., et al., Hemato-critical issues in quantitative analysis of dried blood spots: challenges and solutions. Bioanalysis, 2013. 5(16): p. 2023-2041. 41. de Vries, R., et al., The effect of hematocrit on bioanalysis of DBS: results from the EBF DBS-microsampling consortium. Bioanalysis, 2013. 5(17): p. 2147-2160. 42. Berm, E.J.J., et al., A clinical validation study for application of DBS in therapeutic drug monitoring of antidepressants. Bioanalysis, 2016. 8(5): p. 413-424. 43. Oliveira, R.V., J. Henion, and E.R. Wickremsinhe, Automated direct extraction and analysis of dried blood spots employing on-line SPE high-resolution accurate mass bioanalysis. Bioanalysis, 2014. 6(15): p. 2027-2041. 44. Li, F.M., et al., Perforated dried blood spots: a novel format for accurate microsampling. Bioanalysis, 2011. 3(20): p. 2321-2333. 45. Zheng, N.Y., et al., 'Center punch' and 'whole spot' bioanalysis of apixaban in human dried blood spot samples by UHPLC-MS/MS. Journal of Chromatography B-Analytical Technologies in the Biomedical and Life Sciences, 2015. 988: p. 66-74. 46. John, H., et al., Procedures for Analysis of Dried Plasma Using Microsampling Devices to Detect Sulfur Mustard-Albumin Adducts for Verification of Poisoning. Analytical Chemistry, 2016. 88(17): p. 8787-8794. 47. Wickremsinhe, E.R., et al., Preclinical bridging studies: understanding dried blood spot and plasma exposure profiles. Bioanalysis, 2013. 5(2): p. 159-170. 48. Xu, Y., et al., Merck's perspective on the implementation of dried blood spot technology in clinical drug development - why, when and how. Bioanalysis, 2013. 5(3): p. 341-350. 49. Jager, N.G.L., et al., Use of dried blood spots for the determination of serum concentrations of tamoxifen and endoxifen. Breast Cancer Research and Treatment, 2014. 146(1): p. 137-144. 50. Milosheska, D., I. Grabnar, and T. Vovk, Dried blood spots for monitoring and individualization of antiepileptic drug treatment. European Journal of Pharmaceutical Sciences, 2015. 75: p. 25-39. 51. Foerster, K.I., et al., Dried-Blood-Spot Technique to Monitor Direct Oral Anticoagulants: Clinical Validation of a UPLC-MS/MS-Based Assay. Anal Chem, 2018. 90(15): p. 9395-9402. 52. Chen, G.Y., et al., Quantification of amlodipine in dried blood spot samples by high performance liquid chromatography tandem mass spectrometry. Journal of Chromatography B-Analytical Technologies in the Biomedical and Life Sciences, 2018. 1072: p. 252-258. 53. McDade, T.W., S. Williams, and J.J. Snodgrass, What a drop can do: Dried blood spots as a minimally invasive method for integrating biomarkers into population-based research. Demography, 2007. 44(4): p. 899-925. 54. Organization, W.H., WHO manual for HIV drug resistance testing using dried blood spot specimens. March, 2010. 55. Tilea, I., et al., Determination of Apixaban Levels in Human Plasma by a High-Throughput Liquid Chromatographic Tandem Mass Spectrometry Assay. Revista Romana De Medicina De Laborator, 2015. 23(1): p. 115-125. 56. Kuhn, J., et al., UPLC-MRM Mass Spectrometry Method for Measurement of the Coagulation Inhibitors Dabigatran and Rivaroxaban in Human Plasma and Its Comparison with Functional Assays. Plos One, 2015. 10(12): p. 19. 57. Zhang, W.L., et al., Determination of rivaroxaban, apixaban and edoxaban in rat plasma by UPLC-MS/MS method. Journal of Thrombosis and Thrombolysis, 2016. 42(2): p. 205-211. 58. Youhnovski, N., et al., Pre-cut dried blood spot (PCDBS): an alternative to dried blood spot (DBS) technique to overcome hematocrit impact. Rapid Communications in Mass Spectrometry, 2011. 25(19): p. 2951-2958. 59. Liu, G.W., et al., Strategy of Accelerated Method Development for High-Throughput Bioanalytical Assays Using Ultra High-Performance Liquid Chromatography Coupled with Mass Spectrometry. Analytical Chemistry, 2009. 81(22): p. 9225-9232. 60. Juhascik, M.P. and A.J. Jenkins, Comparison of Liquid/Liquid and Solid-Phase Extraction for Alkaline Drugs. Journal of Chromatographic Science, 2009. 47(7): p. 553-557. 61. Liao, H.W., et al., Using a postcolumn-infused internal standard for correcting the matrix effects of urine specimens in liquid chromatography-electrospray ionization mass spectrometry. Journal of Chromatography A, 2014. 1327: p. 97-104. 62. Koster, R.A., et al., Fast LC-MS/MS analysis of tacrolimus, sirolimus, everolimus and cyclosporin A in dried blood spots and the influence of the hematocrit and immunosuppressant concentration on recovery. Talanta, 2013. 115: p. 47-54. 63. Tsai, I.L., et al., An on-spot internal standard addition approach for accurately determining colistin A and colistin B in dried blood spots using ultra high-performance liquid chromatography-tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2017. 145: p. 783-793. 64. Berm, E.J.J., et al., A simple dried blood spot method for therapeutic drug monitoring of the tricyclic antidepressants amitriptyline, nortriptyline, imipramine, clomipramine, and their active metabolites using LC-MS/MS. Talanta, 2015. 134: p. 165-172. 65. Koster, R.A., et al., Dried blood spot analysis of creatinine with LC-MS/MS in addition to immunosuppressants analysis. Analytical and Bioanalytical Chemistry, 2015. 407(6): p. 1585-1594. 66. Barco, S., et al., Volumetric adsorptive microsampling-liquid chromatography tandem mass spectrometry assay for the simultaneous quantification of four antibiotics in human blood: Method development, validation and comparison with dried blood spot. Journal of Pharmaceutical and Biomedical Analysis, 2017. 145: p. 704-710. 67. Emmons, G. and M. Rowland, Pharmacokinetic considerations as to when to use dried blood spot sampling. Bioanalysis, 2010. 2(11): p. 1791-6. 68. Biagiotti, S., et al., Drug Delivery by Red Blood Cells. Iubmb Life, 2011. 63(8): p. 621-631. 69. McGrail, R., et al., Stability of direct oral anticoagulants in whole blood and plasma from patients in steady state treatment. Thrombosis Research, 2016. 148: p. 107-110. 70. Linder, C., et al., Comparison between dried blood spot and plasma sampling for therapeutic drug monitoring of antiepileptic drugs in children with epilepsy: A step towards home sampling. Clinical Biochemistry, 2017. 50(7-8): p. 418-424. 71. Enderle, Y., et al., Dried Blood Spot Technique for the Monitoring of Ambrisentan, Bosentan, Sildenafil, and Tadalafil in Patients with Pulmonary Arterial Hypertension. Analytical Chemistry, 2015. 87(24): p. 12112-12120. 72. Clinical Pharmacology/Biopharmaceutics Review (Addendum to Previous Review −DARRTS date: 02/15/2012); Review of Apixaban (Eliquis), NDA 202-155, Reference ID 3232801; Center for Drug Evaluation and Research, 2012. 73. Clinical Pharmacology Review NDA 22-512, Dabigatran; Center for Drug Evaluation and Research, 2010. 74. Office of Clinical Pharmacology Review Addenum to April 6, 2009 Review; Review of Rivaroxaban (Xarelto), NDA 22-406, Reference ID 2955610; Center for Drug Evaluation and Research, 2011. 75. Kok, M.G.M. and M. Fillet, Volumetric absorptive microsampling: Current advances and applications. Journal of Pharmaceutical and Biomedical Analysis, 2018. 147: p. 288-296. 76. Kip, A.E., et al., Volumetric absorptive microsampling (VAMS) as an alternative to conventional dried blood spots in the quantification of miltefosine in dried blood samples. Journal of Pharmaceutical and Biomedical Analysis, 2017. 135: p. 160-166. 77. Denniff, P. and N. Spooner, Volumetric Absorptive Microsampling: A Dried Sample Collection Technique for Quantitative Bioanalysis. Analytical Chemistry, 2014. 86(16): p. 8489-8495. 78. O'Mara, M., et al., The effect of hematocrit and punch location on assay bias during quantitative bioanalysis of dried blood spot samples. Bioanalysis, 2011. 3(20): p. 2335-2347. 79. Spooner, N., et al., A device for dried blood microsampling in quantitative bioanalysis: overcoming the issues associated with blood hematocrit. Bioanalysis, 2015. 7(6): p. 653-659. 80. Capiau, S., et al., Prediction of the Hematocrit of Dried Blood Spots via Potassium Measurement on a Routine Clinical Chemistry Analyzer. Analytical Chemistry, 2013. 85(1): p. 404-410. 81. Capiau, S., et al., Correction for the Hematocrit Bias in Dried Blood Spot Analysis Using a Nondestructive, Single-Wavelength Reflectance-Based Hematocrit Prediction Method. Analytical Chemistry, 2018. 90(3): p. 1795-1804. 82. Liao, H.W., et al., Identification of potential sphingomyelin markers for the estimation of hematocrit in dried blood spots via a lipidomic strategy. Analytica Chimica Acta, 2018. 1003: p. 34-41. 83. Liao, H.W., et al., Quantification of endogenous metabolites by the postcolumn infused-internal standard method combined with matrix normalization factor in liquid chromatography-electrospray ionization tandem mass spectrometry. Journal of Chromatography A, 2015. 1375: p. 62-68. 84. Ottova-Leitmannova, H.T.T.A., Membrane Biophysics: As Viewed from Experimental Bilayer Lipid Membranes. 2000: p. 41. 85. Ulmer, C.Z., et al., Liquid Chromatography-Mass Spectrometry Metabolic and Lipidomic Sample Preparation Workflow for Suspension-Cultured Mammalian Cells using Jurkat T lymphocyte Cells. J Proteomics Bioinform, 2015. 8(6): p. 126-132. 86. Liao, H.W., et al., Quantification of target analytes in various biofluids using a postcolumn infused-internal standard method combined with matrix normalization factors in liquid chromatography-electrospray ionization mass spectrometry. Journal of Chromatography A, 2014. 1358: p. 85-92. 87. Liao, H.W., et al., Development of a Postcolumn Infused-Internal Standard Liquid Chromatography Mass Spectrometry Method for Quantitative Metabolomics Studies. Journal of Proteome Research, 2017. 16(2): p. 1097-1104. 88. Lee, D.Y., et al., Comparative evaluation of extraction methods for simultaneous mass-spectrometric analysis of complex lipids and primary metabolites from human blood plasma. Analytical and Bioanalytical Chemistry, 2014. 406(28): p. 7275-7286. 89. Matyash, V., et al., Lipid extraction by methyl-tert-butyl ether for high-throughput lipidomics. Journal of Lipid Research, 2008. 49(5): p. 1137-1146. 90. Koulman, A., et al., The development and validation of a fast and robust dried blood spot based lipid profiling method to study infant metabolism. Metabolomics, 2014. 10(5): p. 1018-1025. 91. Aristizabal Henao, J.J., et al., Tailored Extraction Procedure Is Required To Ensure Recovery of the Main Lipid Classes in Whole Blood When Profiling the Lipidome of Dried Blood Spots. Anal Chem, 2016. 88(19): p. 9391-9396. 92. Cajka, T. and O. Fiehn, Toward Merging Untargeted and Targeted Methods in Mass Spectrometry-Based Metabolomics and Lipidomics. Analytical Chemistry, 2016. 88(1): p. 524-545. 93. Faller, A., et al., Stability of phosphatidylethanol species in spiked and authentic whole blood and matching dried blood spots. Int J Legal Med, 2013. 127(3): p. 603-10. 94. Drzymala-Czyz, S., et al., Whole blood glycerophospholipids in dried blood spots - a reliable marker for the fatty acid status. Chem Phys Lipids, 2017. 207(Pt A): p. 1-9. 95. Phillips, G.B. and N.S. Roome, Phospholipids of human red blood cells. Proc Soc Exp Biol Med, 1959. 100(3): p. 489-92. 96. Rose, H.G. and M. Oklander, IMPROVED PROCEDURE FOR THE EXTRACTION OF LIPIDS FROM HUMAN ERYTHROCYTES. J Lipid Res, 1965. 6: p. 428-31. 97. Bystricka, Z. and Z. Durackova, Gas chromatography determination of fatty acids in the human erythrocyte membranes - A review. Prostaglandins Leukotrienes and Essential Fatty Acids, 2016. 115: p. 35-40. 98. Metherel, A.H. and K.D. Stark, The stability of blood fatty acids during storage and potential mechanisms of degradation: A review. Prostaglandins Leukot Essent Fatty Acids, 2016. 104: p. 33-43. 99. Metherel, A.H., et al., Butylated hydroxytoluene can protect polyunsaturated fatty acids in dried blood spots from degradation for up to 8 weeks at room temperature. Lipids in Health and Disease, 2013. 12: p. 9. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/79033 | - |
dc.description.abstract | 採血卡取樣技術在疾病篩檢上已有著悠久的歷史。由於個人化醫療的觀念亦趨重要,此採樣方法用作為一個普遍的醫療評估工具已於現今得到很高的重視。儘管採血卡取樣技術有很多的優點,但將其應用在臨床上例行的生物檢測仍然存在很多挑戰。本論文中所建立的分析方法為運用液相層析串聯式質譜儀並結合管柱後灌注內標法以分析採血卡上的化合物。
本論文第一部分,我們執行方法開發及確效以定量採血卡上三種新型口服抗凝血藥物,包括dabigatran、rivaroxaban、apixaban。利用管柱後灌注內標法校正在質譜儀內的基質效應和估計採血卡上的血液體積。在最佳化的分析條件下,此方法能在4分鐘內完成三種抗凝血藥物的定量分析。當使用0.1%甲酸並搭配乙腈(3:7 v/v)作為萃取液時,三個藥物萃取率可高達90%以上。選用[13C6]-rivaroxaban作為管柱後灌注法的內標準品,其估計體積的準確度介於87.1-119.8% (n=7). 此外,三個藥物沒有顯著受到5個不同血比溶的影響。在全部測試濃度的確效結果均顯示準確度介在88.9-104.3%,且同日內之重覆性及異日間之再現性精密度的相對標準差皆小於10.0%。本分析方法所使用的三種藥物在採血卡檢體建立線性的相關係數皆大於0.99,定量極限皆小於0.6 ng mL-1。三種藥物在採血卡檢體內於室溫、4°C及-20°C的條件下存放一個月後的安定性良好(91.0-111.4%)。我們成功地將管柱後灌注內標法用於定量採血卡中三種新型口服抗凝血藥物,研究結果指出此方法可以有效地用在測量採血卡上的藥物濃度。 第二部分我們進一步評估本實驗室先前找到的兩種磷脂醯乙醇胺用來估計血比容的準確度。先使用水浸潤並搭配Folch萃取法,結果顯示磷脂醯乙醇胺16:0/20:4及16:0/18:1在採血卡檢體的萃取率分別是84.6%及93.4%。我們選擇外生性的磷脂醯乙醇胺17:1作為管柱後灌注法的內標準品以校正基質效應,並在質譜端使用負離子模式以增加選擇性。在分析方法的最適化條件下,我們定量採血卡中的兩個磷脂醯乙醇胺並發現其兩者的濃度與血比容值呈現高度線性相關性(R2>0.98)。因此進一步使用此兩個內標估測60個臨床採血卡檢體的血比容值,結果顯示全部的樣品的估計偏差皆小於15%。帶入布蘭德-奧特曼差異分析方法後顯示超過90%的檢體量落在95%信賴區間內,從山形圖可知磷脂醯乙醇胺16:0/20:4及16:0/18:1的平均偏差分別為0.3及-2.5。我們的結果顯示此二個磷脂醯乙醇胺極具潛力作為估計採血卡檢體中的血比容值的標誌。 總結本研究為使用液相層析串聯式質譜儀建立方法;分別用於定量採血卡檢體內的三種新型抗凝血藥物,及估計採血卡檢體內血比容。此兩個簡易且高效的分析方法可提供作為療劑監測的一個新方法,以協助個人化醫療並可以更廣泛將採血卡應用在臨床上。 | zh_TW |
dc.description.abstract | Dried blood spots (DBSs) sampling technique has had a long history in disease screening. Recently, it has gained high attention as a common medical assessment tool because of the growing importance of personalized medicine. In spite of numerous advantages respecting the DBS sampling technique, this powerful sampling tool still faces challenges in the application of routine clinical bioanalysis. In this study, we develop analytical methods for DBS analysis by a liquid chromatography-tandem mass spectrometry combined with postcolumn infused-internal standard (PCI-IS) approach.
In the first part of this thesis, we developed and validated a method for quantification of three NOACs including dabigatran, rivaroxaban and apixaban in DBS. The PCI-IS method was adapted for correction of matrix effects in LC-ESI-MS and estimation of blood volumes on DBS cards. Under optimal conditions, three NOACs could be quantified in a single run within 5min. Over 90% of the recovery could be achieved when using 0.1% formic acid in water with acetonitrile (3:7 v/v) as the extraction solution. [13C6]-rivaroxaban was selected as the PCI-IS and the accuracy for volume estimation was between 87.1% and 119.8% (n=7). Furthermore, the result from hematocrit effect of three NOACs showed no significant variation for 5 different hematocrit (HCT) levels. Validation results demonstrated that the accuracies were among 88.9-104.3%, and intra-day and inter-day precisions were all below 10.0% for all test concentrations. The calibration curves of DBS samples for the analytes had coefficients of determination higher than 0.99, and the limits of detection were all below 0.6 ng mL-1. The stability of three NOACs revealed good stability (91.0-111.4%) in the DBS samples after one months of storage at room temperature, 4 °C and -20 °C. We successfully applied the PCI-IS method for quantification of NOACs in DBS, and the result revealed PCI-IS is an effective strategy for measuring drug concentrations in DBS. In the second part, we further evaluated the accuracies of two potential phosphatidylethanolamine (PE) markers identified in our lab for estimation of HCT values. Using water pre-rinsed in combination with Folch extraction showed good recoveries with 84.6% and 93.4% for PE 16:0/20:4 and PE 16:0/18:1, respectively. We selected the exogenous lysoPE 17:1 as the PCI-IS for correction of matrix effect, and applied negative mode LC-ESI-MS to enhance selectivity. Under the optimized condition, we quantified these two PEs in the DBS samples and found the high correlation between the concentration of PEs and the HCT values of DBS samples (R2>0.98). Thus, PE 16:0/18:1 and PE 16:0/20:4 were further applied to estimate the HCT values of 60 DBS samples obtained from patients. Finally, the results showed that all of samples were presented less than 15% estimation error. The Bland and Altman analysis showed more than 90% of DBS samples within 95% CI. The mean biases from mountain plot were 0.3 and -2.5 for PE 16:0/18:1 and PE 16:0/20:4, respectively. Our results indicated that PE 16:0/18:1 and PE 16:0/20:4 exhibited high potential to serve as makers to estimate HCT values for the DBS samples. In conclusion, we established a analytical methods for accurate quantification of NOACs in DBS samples and estimation of HCT levels by LC-ESI-MS. The developed two simple and efficient methods can offer a new strategy for routine therapeutic drug monitoring (TDM) to improve personalized medicine and expand applications of DBS technique in clinical use. | en |
dc.description.provenance | Made available in DSpace on 2021-07-11T15:38:18Z (GMT). No. of bitstreams: 1 ntu-107-R06423002-1.pdf: 3722506 bytes, checksum: d7919e9d0f05ee1b8ee2ffa99c6b49a7 (MD5) Previous issue date: 2018 | en |
dc.description.tableofcontents | 中文摘要 I
Abstract V Contents IX Figure contents XI Table contents XIII Part I: Using the Postcolumn Infused-Internal Standard Method to Quantify Novel Oral Anticoagulants in Dried Blood Spots by LC-ESI-MS 1 1.1 Introduction 2 1.1.1 The importance of new oral anticoagulants (NOACs) concentration monitoring 2 1.1.2 Dried blood spot and its’ advantage 4 1.1.3 Mass spectrometry for DBS analysis 6 1.1.4 Challenges of using DBS sampling technique in clinical practice 7 1.1.5 Exploration of a quantitative relationship between the blood and plasma 9 1.1.6 Current methods for quantification of NOACs in DBS 10 1.7 Research aims 12 1.2. Material and Methods 12 1.2.1 Chemicals and reagents 12 1.2.2 UHPLC-ESI-MS system 13 1.2.3 Standard solutions and calibration standards 14 1.2.4 Samples collection 15 1.2.5 DBS sample preparation 15 1.2.6 Dried blood spot extraction 16 1.2.7 Method validation 17 1.2.8 Data analysis 21 1.3 Results and discussion 21 1.3.1 Method development 21 1.3.2 Method validation 29 1.4 Conclusion 33 1.5 Figures 35 1.6 Tables 42 Part Ⅱ: Development of a Postcolumn Infused-Internal Standard Method to Quantify Phosphatidylethanolamine for the Estimation of Hematocrit in Dried Blood Spots by LC-ESI-MS 48 2.1 Introduction 49 2.1.1 Background of dried blood spot 49 2.1.2 Current strategies for overcoming the hematocrit problem and their limitations 50 2.2 Experimental section 52 2.2.1 Chemicals and Materials 52 2.2.2 The UHPLC-ESI-MS system combined with PCI-IS method 53 2.2.3 Standard solutions and calibration standards 54 2.2.4 Samples preparation 55 2.2.5 Preparation of artificial blood samples to study the correlation between proposed markers and HCT values 56 2.2.6 Linearity, limit of detections (LODs), and limit of quantifications (LLOQs) 56 2.2.7 Extraction recovery and stability 56 2.2.8 PCI-IS method combined with MNF strategy 58 2.2.9 Clinical sample collection 59 2.2.10 Data analysis 59 2.3 Results and discussion 60 2.3.1 Method development 60 2.3.2 Method validation 63 2.4 Conclusions 66 2.5 Figures 68 2.6 Tables 74 References 75 | |
dc.language.iso | en | |
dc.title | 第一部份:以液相層析質譜儀結合柱後注入內標法定量採血卡上的新型抗凝血藥物
第二部分:建立液相層析質譜儀結合柱後注入內標法定量磷脂醯乙醇胺以測量採血卡上的血比容 | zh_TW |
dc.title | Part I: Using the Postcolumn Infused-Internal Standard Method to Quantify Novel Oral Anticoagulants in Dried Blood Spots by LC-ESI-MS
Part II: Development of a Postcolumn Infused-Internal Standard Method to Quantify Phosphatidylethanolamine for the Estimation of Hematocrit in Dried Blood Spots by LC-ESI-MS | en |
dc.type | Thesis | |
dc.date.schoolyear | 106-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 蔡依琳(I-Lin Tsai),湯頌君(Sung-Chun Tang) | |
dc.subject.keyword | 採血卡,新型口服抗凝血藥,血液體積,血比容,柱後注入內標,質譜儀, | zh_TW |
dc.subject.keyword | dried blood spot (DBS),novel oral anticoagulants (NOACs),blood volume,hematocrit effect,post-column infused internal standard (PCI-IS),mass spectrometry, | en |
dc.relation.page | 83 | |
dc.identifier.doi | 10.6342/NTU201803315 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2018-08-14 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 藥學研究所 | zh_TW |
顯示於系所單位: | 藥學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-107-R06423002-1.pdf 目前未授權公開取用 | 3.64 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。